Skip to content

Intracranial vessel wall MR imaging at 3.0 and 7.0 tesla in patients with TIA or ischemic stroke of the posterior circulation

Intracranial vessel wall MR imaging at 3.0 and 7.0 tesla in patients with TIA or ischemic stroke of the posterior circulation - PIVI Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON47288
Enrollment
100
Registered
2013-07-16
Start date
2013-11-07
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerosis hardening of the arteries

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: >= 18 years of age;Additional inclusion criteria for ischemic stroke / TIA patients: - TIA or ischemic stroke in the posterior circulation territory (= supplied via the vertebral and basilar arteries or their branches) - Possibility to perform MRI scanning within 3 months after onset of relevant ischemic symptoms

Exclusion criteria

Exclusion criteria: - Allergic reaction to gadolinium or one of the constituents of its solution for administration - Impossibility to undergo MRI (claustrophobia, implants or metal objects in or around the body) - Severely impaired renal function (severe renal insufficiency, GFR

Design outcomes

Primary

MeasureTime frame
The presence or absence of intracranial vessel wall abnormalities in arteries of the intracranial posterior circulation. Presence of atherosclerosis is defined as any irregularity of the arterial vessel wall.

Secondary

MeasureTime frame
- Number of vessel wall abnormalities in the intracranial vessel wall MRI scan at 7.0 tesla as compared to 3.0 tesla. - Characteristics of intracranial vessel wall atheroma, by discriminating different MRI signal intensities in the vessel wall atheroma. - The clinical outcome measures (e.g. occurrence of vascular events, level of handicap, current medication) collected during follow-up.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)